See full prescribing information for PAROXETINE TABLETS, USP. PAROXETINE tablets, USP, for oral use Initial U.S. Approval: 1992 WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and...
37.5 mg blue tablets ndc 60505-4379-3 bottles of 30 (one face is plain and the other is engraved with 37.5) store at or below 20° to 25°c (68° to 77°f); excursions permitted between 15° to 30°c (59° to 30°f [see usp controlled room temperature ]. manufactured by: ...
6 and simethicone emulsion, USP.Each film-coated tablet contains paroxetine hydrochloride equivalent to paroxetine as follows: 10 mg-yellow (scored); 20 mg-pink (scored); 30 mg-blue, 40 mg-green. Inactive ingredients consist of dibasic calcium phosphate dihydrate, hydroxypropyl methylcellulose, ...
The present invention provides for stable pharmaceutical compositions of paroxetine hydrochloride and processes for their preparation. An effective amount of povidone is used in the present invention, by the wet granulation method of tablet preparation, as a binder to produce tablets that are not suscep...
Paroxetine mesylate is an odorless, off-white powder, having a melting point range of 147° to 150°C and a solubility of more than 1 g/ml in water. Tablets Each oval, film-coated tablet contains paroxetine mesylate equivalent to paroxetine as follows: 10 mg (white); 20 mg (scored, dar...
37.5 mg blue tablets ndc 60505-4379-3 bottles of 30 (one face is plain and the other is engraved with 37.5) store at or below 20° to 25°c (68° to 77°f); excursions permitted between 15° to 30°c (59° to 30°f [see usp controlled room temperature ]. manufactured by: ...